Good day, ladies and gentlemen, and welcome to the SIGA Technologies Quarterly Business Update Conference Call. [Operator Instructions] As a reminder, this conference call is being recorded. I would now like to turn the conference over to your host, Mr. Rob Fink of KCSA Investor Relations. Mr. Fink, you may begin.

Thank you, and thank you, all, for joining us today. This is Rob Fink of KCSA, Investor Relations Consultant of SIGA Technologies. Hosting the call today is Dr. Eric Rose, Chief Executive Officer; and Daniel Luckshire, Chief Financial Officer. Today's call is being simultaneously webcast and is available on SIGA's website. A replay of the call will be -- also be available in a recorded format on the company's website. Before we begin today, I would like to remind everyone that this conference contains statements that constitute forward-looking statements. A Safe Harbor statement covering this call will be read at the end of the call and can be found in the company's press release for financial results for the second quarter ended June 30, 2014. With that, I'd like to turn the call over to Dr. Rose.

Thanks, Rich. Good afternoon, and thank you, all, for joining us. Let me start with an update on the biodefense business. In July, approximately 115,000 courses of Tecovirimat or ST-246 were accepted into the Strategic National Stockpile. With the delivery and acceptance of these courses, we received $15.3 million in July pursuant to our procurement contract with BARDA. Cumulatively, as of the end of July, we've delivered 1.3 million courses of Tecovirimat, and we have received close to $200 million from the BARDA contract, excluding expense reimbursement payments. Going forward, we plan to deliver approximately 710,000 courses by the end of the -- additional courses by the end of the first quarter of 2015, which we expect would generate additional gross proceeds of $89 million. Moreover, SIGA's eligible under the BARDA contract for an additional approximately $123 million of payments for the successful submission and approval of the Tecovirimat NDA. I'd like to note that FDA approval Tecovirimat is strategically important to SIGA. We believe that FDA approval will aid our international business development efforts and may make additional domestic markets viable. Beyond the biodefense business, I'd like to talk about another avenue for value creation, strategic investments. We believe that acquiring and licensing or collaborating on clinical stage development programs could expand and broaden SIGA's scope and could offer a favorable time horizon for value creation. Additionally and importantly, strategic investments could also benefit from being supported and supplemented by SIGA's existing infrastructure and expertise. Potentially adding clinical stage development programs to our existing biodefense business would represent a natural continuation of SIGA's long-term evolution. The evolution started 3 years ago with the signing of the BARDA contract. It has been pushed along through diligent performance on the contract, and its focus has been sharpened with the optimization program that was put in place late last year. The end goal of the evolution is to use SIGA's infrastructure, expertise and resources to maximize long-term value. At this point, we've completed our prepared remarks for our business operations and will now open the line for questions.

[Operator Instructions] Our first question is from Joaquin Horton with Raymond James.

I just want to ask a couple of questions. Also 9 months ago, you mentioned that you were going to try to license or do something with the products that we had developed like dengue fever and Lassa fever and the other projects we were working on like Ebola. Have we had any success in marketing that idea or licensing it?

We have not completed any transaction with regard to any of those programs. But as we said then, it still remains the case now that, that is our intention. And we've been actively seeking such collaboration.

So in the number of courses that we are going to deliver the 710,000, how many of those courses are going to be -- I know we had to deliver 300,000 pursuant to the contract earlier without receiving any payment, and I believe something over 250,000 has already been delivered, is that correct?

That is correct, Joaquin. This is Dan. Of the 710,000, 670,000 approximately will be billed and invoiced. It's 40,000 of the free of charge items.

[Operator Instructions] All right. I'm not showing any further questions. Please proceed with any closing remarks.

Great. Thank you. As a reminder, this call included certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 as amended, including statements regarding the efficacy or potential product, the timeline for bringing such products to market and to continue development and possible eventual approval for such products. Forward-looking statements are based on management's estimates, assumptions and projections and are subject to uncertainties, many of which are beyond SIGA's control. Actual results may differ materially from those anticipated in any forward-looking statements. Factors that may cause such differences include risks due to the potential products that appear promising to SIGA where its collaborators cannot be shown to be effective or safe in subsequent preclinical or clinical trials; SIGA or its collaborators will not obtain a appropriate necessary governmental approval to market these or other potential products; SIGA may not be able to obtain anticipated funding for its development projects or other funding needed; SIGA may not be able to secure funding from anticipated government contracts and grants; SIGA may not be able to secure or enforce sufficient legal rights in its product, including patent protection for its products; any challenges to SIGA's patents and other proprietary rights as adversely determined could affect its business, and even if determined favorably, could be costly. Regulatory requirements applicable to SIGA's products may result in the need for further or additional testing or documentation that will deploy or prevent seeking or obtaining needed approvals; U.S. Biomedical Advanced Research and Development Authority may not complete the procurement set forth in its solicitation to the acquisition of the smallpox antiviral for the Strategic National Stockpile or may incomplete on different terms; any contractual award we may receive to supply smallpox antiviral may be subject to one or more protests, which may…

Ladies and gentlemen, thank you for participating in today's conference. This does conclude the program, and you may all disconnect. Everyone, have a great day.